Skip to main content
    • Aa
    • Aa

Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases

  • Mariola J. Edelmann (a1), Benjamin Nicholson (a2) and Benedikt M. Kessler (a3)

Recent advances in the development and discovery of pharmacological interventions within the ubiquitin–proteasome system (UPS) have uncovered an enormous potential for possible novel treatments of neurodegenerative disease, cancer, immunological disorder and microbial infection. Interference with proteasome activity, although initially considered unlikely to be exploitable clinically, has already proved to be very effective against haematological malignancies, and more specific derivatives that target subsets of proteasomes are emerging. Recent small-molecule screens have revealed inhibitors against ubiquitin-conjugating and -deconjugating enzymes, many of which have been evaluated for their potential use as therapeutics, either as single agents or in synergy with other drugs. Here, we discuss recent advances in the characterisation of novel UPS modulators (in particular, inhibitors of ubiquitin-conjugating and -deconjugating enzymes) and how they pave the way towards new therapeutic approaches for the treatment of proteotoxic disease, cancer and microbial infection.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

      Note you can select to send to either the or variations. ‘’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases
      Available formats
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about sending content to Dropbox.

      Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases
      Available formats
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about sending content to Google Drive.

      Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases
      Available formats
Re-use permitted under a Creative Commons Licence – by-nc-sa
Corresponding author
*Corresponding authors: Benedikt M. Kessler, Henry Wellcome Building for Molecular Physiology, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK. E-mail: and Mariola J. Edelmann, Institute for Genomics, Biocomputing and Biotechnology, Mississippi Agricultural and Forestry, Experimental Station, Pace Seed Lab, Rm 115, Mississippi State University, 650 Stone Boulevard, Mississippi State, MS 39762, USA. E-mail:
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

1 C. Behrends and J.W. Harper (2011) Constructing and decoding unconventional ubiquitin chains. Nature Structural and Molecular Biology 18, 520-528

2 M.J. Clague and S. Urbe (2010) Ubiquitin: same molecule, different degradation pathways. Cell 143, 682-685

3 L. Bedford (2011) Ubiquitin-like protein conjugation and the ubiquitin–proteasome system as drug targets. Nature Reviews. Drug Discovery 10, 29-46

5 P. Guedat and F. Colland (2007) Patented small molecule inhibitors in the ubiquitin proteasome system. BMC Biochemistry 8 (Suppl 1), S14

6 V. Kirkin and I. Dikic (2011) Ubiquitin networks in cancer. Current Opinion in Genetics and Development 21, 21-28

9 W. Sippl , V. Collura and F. Colland (2011) Ubiquitin-specific proteases as cancer drug targets. Future Oncology 7, 619-632

10 M.J. Edelmann and B.M. Kessler (2008) Ubiquitin and ubiquitin-like specific proteases targeted by infectious pathogens: emerging patterns and molecular principles. Biochimica Biophysica et Acta 1782, 809-816

11 M.K. Isaacson and H.L. Ploegh (2009) Ubiquitination, ubiquitin-like modifiers, and deubiquitination in viral infection. Cell Host and Microbe 5, 559-570

12 H.A. Lindner (2007) Deubiquitination in virus infection. Virology 362, 245-256

13 S.M. Nijman (2005) A genomic and functional inventory of deubiquitinating enzymes. Cell 123, 773-786

14 F.E. Reyes-Turcu , K.H. Ventii and K.D. Wilkinson (2009) Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annual Review of Biochemistry 78, 363-397

15 C.M. Pickart and M.J. Eddins (2004) Ubiquitin: structures, functions, mechanisms. Biochimica Biophysica et Acta 1695, 55-72

16 D. Chen (2011) Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Current Cancer Drug Targets 11, 239-53

17 C.T. Kouroukis (2011) A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172). Leukemia and Lymphoma 52, 394-399

18 R. Verma (2004) Ubistatins inhibit proteasome-dependent degradation by binding the ubiquitin chain. Science 306, 117-120

19 J.S. Schneekloth Jr, and C.M. Crews (2011) Natural product inhibitors of the ubiquitin-proteasome pathway. Current Drug Targets 12, 1581-94

20 H. Yang (2006) Celastrol, a triterpene extracted from the Chinese “Thunder of God Vine,” is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Research 66, 4758-4765

21 K.R. Landis-Piwowar (2007) A novel prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate as a potential anticancer agent. Cancer Research 67, 4303-4310

22 D. Chen (2006) Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Research 66, 10425-10433

23 R.E. Tiedemann (2009) Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo. Blood 113, 4027-4037

24 N.R. Jana (2004) Inhibition of proteasomal function by curcumin induces apoptosis through mitochondrial pathway. Journal of Biological Chemistry 279, 11680-11685

25 M. Izumikawa (2011) JBIR-22, an inhibitor for protein–protein interaction of the homodimer of proteasome assembly factor 3. Journal of Natural Products 73, 628-631

26 A. Ludwig (2005) Effect of statins on the proteasomal activity in mammalian endothelial and vascular smooth muscle cells. Biochemical Pharmacology 70, 520-526

27 M. Basler (2009) The proteasome inhibitor bortezomib enhances the susceptibility to viral infection. Journal Immunology 183, 6145-6150

28 A.C. Mirabella (2011) Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and Carfilzomib. Chemistry and Biology 18, 608-618

29 A.M. Ruschak (2011) Novel proteasome inhibitors to overcome bortezomib resistance. Journal of the National Cancer Institute 103, 1007-1017

30 Y.K. Ho (2007) LMP2-specific inhibitors: chemical genetic tools for proteasome biology. Chemistry and Biology 14, 419-430

31 A.V. Singh (2011) PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo. British Journal of Haematology 152, 155-163

32 P.M. Kloetzel and F. Ossendorp (2004) Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Current Opinion in Immunology 16, 76-81

33 U. Seifert (2010) Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress. Cell 142, 613-624

34 M. Basler (2010) Prevention of experimental colitis by a selective inhibitor of the immunoproteasome. Journal Immunology 185, 634-641

35 T. Muchamuel (2009) A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nature Medicine 15, 781-787

36 M. Groettrup , C.J. Kirk and M. Basler (2010) Proteasomes in immune cells: more than peptide producers? Nature Reviews. Immunology 10, 73-78

37 S. Hussain , Y. Zhang and P.J. Galardy (2009) DUBs and cancer: the role of deubiquitinating enzymes as oncogenes, non-oncogenes and tumor suppressors. Cell Cycle 8, 1688-1697

38 Y. Pereg (2010) Ubiquitin hydrolase Dub3 promotes oncogenic transformation by stabilizing Cdc25A. Nature Cell Biology 12, 400-406

39 M. Schwickart (2010) Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 463, 103-107

40 M.S. Song (2008) The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature 455, 813-817

41 J. Yuan (2010) USP10 regulates p53 localization and stability by deubiquitinating p53. Cell 140, 384-396

42 J.M. Cummins and B. Vogelstein (2004) HAUSP is required for p53 destabilization. Cell Cycle 3, 689-692

43 M. Li (2004) A dynamic role of HAUSP in the p53-Mdm2 pathway. Molecular Cell 13, 879-886

44 J.M. Cummins (2004) Tumour suppression: disruption of HAUSP gene stabilizes p53. Nature 428, 1 p following 486

45 E. Meulmeester (2005) Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2. Molecular Cell 18, 565-576

46 H. Faustrup (2009) USP7 counteracts SCFbetaTrCP- but not APCCdh1-mediated proteolysis of Claspin. Journal of Cell Biology 184, 13-19

47 A. van der Horst (2006) FOXO4 transcriptional activity is regulated by monoubiquitination and USP7/HAUSP. Nature Cell Biology 8, 1064-1073

49 B. Nicholson and K.G. Suresh Kumar (2011) The multifaceted roles of USP7; new therapeutic opportunities. Cell Biochemistry and Biophysics 60, 61-68

50 F. Colland (2009) Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Molecular Cancer Therapeutics 8, 2286-2295

51 X. Tian (2011) Characterization of selective ubiquitin and ubiquitin-like protease inhibitors using a fluorescence-based multiplex assay format. Assay and Drug Development Technologies 9, 165-173

52 F. Colland (2010) The therapeutic potential of deubiquitinating enzyme inhibitors. Biochemical Society Transactions 38, 137-143

53 B.H. Lee (2010) Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature 467, 179-184

54 Z. Li (2004) Delta12-prostaglandin J2 inhibits the ubiquitin hydrolase UCH-L1 and elicits ubiquitin-protein aggregation without proteasome inhibition. Biochemical and Biophysical Research Communications 319, 1171-1180

55 Y. Liu (2003) Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chemistry and Biology 10, 837-846

56 H. Liu (2010) Modification of ubiquitin-C-terminal hydrolase-L1 by cyclopentenone prostaglandins exacerbates hypoxic injury. Neurobiology of Disease 41, 318-28

57 L.M. Koharudin (2010) Cyclopentenone prostaglandin-induced unfolding and aggregation of the Parkinson disease-associated UCH-L1. Proceedings of the National Academy of Sciences of the United States of America 107, 6835-6840

58 K. Ratia (2008) A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proceedings of the National Academy of Sciences of the United States of America 105, 16119-16124

60 R.L. Williams and S. Urbe (2007) The emerging shape of the ESCRT machinery. Nature Reviews. Molecular Cell Biology 8, 355-368

61 E. Mizuno (2006) A deubiquitinating enzyme UBPY regulates the level of protein ubiquitination on endosomes. Traffic 7, 1017-1031

62 M. Colombo (2010) Synthesis and biological evaluation of 9-oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile analogues as potential inhibitors of deubiquitinating enzymes. ChemMedChem 5, 552-558

63 S. Niendorf (2007) Essential role of ubiquitin-specific protease 8 for receptor tyrosine kinase stability and endocytic trafficking in vivo. Molecular and Cellular Biology 27, 5029-5039

64 J.U. Scher and M.H. Pillinger (2009) The anti-inflammatory effects of prostaglandins. Journal of Investigative Medicine 57, 703-708

65 B. Rocca and G.A. FitzGerald (2002) Cyclooxygenases and prostaglandins: shaping up the immune response. International Immunopharmacology 2, 603-630

66 S.G. Harris (2002) Prostaglandins as modulators of immunity. Trends in Immunology 23, 144-150

67 C.E. Clay (1999) Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. Carcinogenesis 20, 1905-1911

68 J.E. Mullally (2001) Cyclopentenone prostaglandins of the J series inhibit the ubiquitin isopeptidase activity of the proteasome pathway. Journal of Biological Chemistry 276, 30366-30373

69 J.E. Mullally and F.A. Fitzpatrick (2002) Pharmacophore model for novel inhibitors of ubiquitin isopeptidases that induce p53-independent cell death. Molecular Pharmacology 62, 351-358

70 B.J. Baker and P.J. Scheuer (1994) The punaglandins: 10-chloroprostanoids from the octocoral Telesto riisei. Journal of Natural Products 57, 1346-1353

71 S.M. Verbitski (2004) Punaglandins, chlorinated prostaglandins, function as potent Michael receptors to inhibit ubiquitin isopeptidase activity. Journal of Medicinal Chemistry 47, 2062-2070

72 A.H. Mermerian (2007) Structure-activity relationship, kinetic mechanism, and selectivity for a new class of ubiquitin C-terminal hydrolase-L1 (UCH-L1) inhibitors. Bioorganic and Medicinal Chemistry Letters 17, 3729-3732

73 S.M. Wilson (2002) Synaptic defects in ataxia mice result from a mutation in Usp14, encoding a ubiquitin-specific protease. Nature Genetics 32, 420-425

74 C. Anderson (2005) Loss of Usp14 results in reduced levels of ubiquitin in ataxia mice. Journal of Neurochemistry 95, 724-731

75 V. Kapuria (2010) Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Research 70, 9265-9276

76 G.A. Bartholomeusz (2007) Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. Blood 109, 3470-3478

77 L.V. Pham (2010) Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications. Molecular Cancer Therapeutics 9, 2026-2036

78 B. Nicholson (2008) Characterization of ubiquitin and ubiquitin-like-protein isopeptidase activities. Protein Science 17, 1035-1043

79 H.A. Lindner (2005) The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme. Journal of Virology 79, 15199-15208

80 N. Barretto (2005) The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity. Journal of Virology 79, 15189-15198

82 A. Hershko and A. Ciechanover (1998) The ubiquitin system. Annual Review of Biochemistry 67, 425-479

83 A. Yaron (1997) Inhibition of NF-kappa-B cellular function via specific targeting of the I-kappa-B-ubiquitin ligase. EMBO Journal 16, 6486-6494

84 G. Melino (2008) Itch: a HECT-type E3 ligase regulating immunity, skin and cancer. Cell Death and Differentiation 15, 1103-1112

85 D. Gomez-Martin , M. Diaz-Zamudio and J. Alcocer-Varela (2008) Ubiquitination system and autoimmunity: the bridge towards the modulation of the immune response. Autoimmunity Reviews 7, 284-290

86 M.J. Nyhan , G.C. O'Sullivan and S.L. McKenna (2008) Role of the VHL (von Hippel–Lindau) gene in renal cancer: a multifunctional tumour suppressor. Biochemical Society Transactions 36, 472-478

87 J. Momand (1998) The MDM2 gene amplification database. Nucleic Acids Research 26, 3453-3459

88 L.T. Vassilev (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848

90 S.J. Duncan (2001) Isolation and structure elucidation of Chlorofusin, a novel p53-MDM2 antagonist from a Fusarium sp. Journal of the American Chemical Society 123, 554-560

91 S. Tsukamoto (2006) Hexylitaconic acid: a new inhibitor of p53-HDM2 interaction isolated from a marine-derived fungus, Arthrinium sp. Bioorganic and Medicinal Chemistry Letters 16, 69-71

93 R. Stoll (2001) Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry 40, 336-344

94 T. Ito (2010) Identification of a primary target of thalidomide teratogenicity. Science 327, 1345-1350

95 Y. Yang (2007) Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Research 67, 9472-9481

96 T.A. Soucy (2009) An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458, 732-736

97 S. Endo (2010) Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells. Cancer Science 102, 605-13

98 Y. Tabe (2009) MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma. Clinical Cancer Research 15, 933-942

99 M.G. Ooi (2009) Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Clinical Cancer Research 15, 7153-7160

100 N. Issaeva (2004) Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nature Medicine 10, 1321-1328

101 Y. Yang (2005) Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 7, 547-559

102 J.G. Allen (2009) Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein–protein interaction. Journal of Medicinal Chemistry 52, 7044-7053

103 K. Ding (2006) Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. Journal of Medicinal Chemistry 49, 3432-3435

104 S. Shangary (2008) Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proceedings of the National Academy of Sciences of the United States of America 105, 3933-3938

105 R.C. Clark (2009) Evaluation of chlorofusin, its seven chromophore diastereomers, and key analogues. Tetrahedron Letters 50, 3151-3153

106 S. Shibata (1994) Anti-tumorigenic chalcones. Stem Cells 12, 44-52

107 A. Modzelewska (2006) Anticancer activities of novel chalcone and bis-chalcone derivatives. Bioorganic and Medicinal Chemistry 14, 3491-3495

109 K.I. Nakayama and K. Nakayama (2006) Ubiquitin ligases: cell-cycle control and cancer. Nature Reviews. Cancer 6, 369-381

110 Q. Chen (2008) Targeting the p27 E3 ligase SCFSkp2 results in p27-and Skp2-mediated cell-cycle arrest and activation of autophagy. Blood 111, 4690-4699

111 S. Orlicky (2010) An allosteric inhibitor of substrate recognition by the SCFCdc4 ubiquitin ligase. Nature Biotechnology 28, 733, U1743

112 M. Aghajan (2010) Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligase. Nature Biotechnology 28, 738-742

113 M.E. Bosch (2008) Recent advances in analytical determination of thalidomide and its metabolites. Journal of Pharmaceutical and Biomedical Analysis 46, 9-17

114 S.C. Bodine (2001) Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294, 1704-1708

115 M.J. Eddins (2011) Targeting the ubiquitin E3 ligase MuRF1 to inhibit muscle atrophy. Cell Biochemistry and Biophysics 60, 113-118

117 G.W. Xu (2010) The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. Blood 115, 2251-2259

118 V. Kapuria (2011) Protein cross-linking as a novel mechanism of action of a ubiquitin-activating enzyme inhibitor with anti-tumor activity. Biochemical Pharmacology 82, 341-9

119 R. Sekizawa (2002) Panepophenanthrin, from a mushroom strain, a novel inhibitor of the ubiquitin-activating enzyme. Journal of Natural Products 65, 1491-1493

120 M. Matsuzawa (2006) Enantio- and diastereoselective total synthesis of (+)-panepophenanthrin, a ubiquitin-activating enzyme inhibitor, and biological properties of its new derivatives. Chemistry, an Asian Journal 1, 845-851

121 S. Tsukamoto (2005) Himeic acid A: a new ubiquitin-activating enzyme inhibitor isolated from a marine-derived fungus, Aspergillus sp. Bioorganic and Medicinal Chemistry Letters 15, 191-194

122 S. Tsukamoto (2008) Leucettamol A: a new inhibitor of Ubc13-Uev1A interaction isolated from a marine sponge, Leucetta aff. microrhaphis. Bioorganic and Medicinal Chemistry Letters 18, 6319-6320

123 D.F. Ceccarelli (2011) An allosteric inhibitor of the human cdc34 ubiquitin-conjugating enzyme. Cell 145, 1075-1087

124 D.P. Xirodimas (2008) Novel substrates and functions for the ubiquitin-like molecule NEDD8. Biochemical Society Transactions 36, 802-806

125 J. Herrmann , L.O. Lerman and A. Lerman (2007) Ubiquitin and ubiquitin-like proteins in protein regulation. Circulation Research 100, 1276-1291

126 Z.Q. Pan (2004) Nedd8 on cullin: building an expressway to protein destruction. Oncogene 23, 1985-1997

127 S.C. Clifford (2001) The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma. Oncogene 20, 5067-5074

128 T.A. Soucy , P.G. Smith and M. Rolfe (2009) Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer. Clinical Cancer Research 15, 3912-3916

129 R.T. Swords (2010) Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood 115, 3796-3800

130 J.E. Brownell (2010) Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Molecular Cell 37, 102-111

G. Nalepa , M. Rolfe and J.W. Harper (2006) Drug discovery in the ubiquitin–proteasome system. Nature Reviews. Drug Discovery 5, 596-613

A.G. Eldridge and T. O'Brien (2010) Therapeutic strategies within the ubiquitin proteasome system. Cell Death and Differentiation 17, 4-13

B. Nicholson (2007) Deubiquitinating enzymes as novel anticancer targets. Future Oncology 3, 191-199

M.P. Dickens , R. Fitzgerald and P.M. Fischer (2010) Small-molecule inhibitors of MDM2 as new anticancer therapeutics. Seminars in Cancer Biology 20, 10-18

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *


Full text views

Total number of HTML views: 11
Total number of PDF views: 100 *
Loading metrics...

Abstract views

Total abstract views: 188 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 28th April 2017. This data will be updated every 24 hours.